Waterford, Ireland - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today it will invest €44m in Genzyme’s biotechnology campus in Waterford, Ireland. The investment will increase the site’s diversity of products by adding the filling of Sanofi’s Lantus® (insulin glargine), the number one insulin brand worldwide. Subject to regulatory approvals, commercial production of Lantus® at Waterford should commence in 2016. The investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.View press release in full